Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
ONTARGET - Ongoing telmisartan alone and in combination with ramipril global endpoint trial und TRANSCEND - Telmisartan randomized assessment study in ACE-I intolerant subjects with cardiovascular disease (30 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 23: TRANSCEND - Telmisartan Randomized AssessmeNt Study in ACE-I INtolerant Subjects with Cardiovascular Disease Abb. 24: TRANSCEND - background Abb. 25: TRANSCEND - objectives Aktuelles Bild - Abb. 26: TRANSCEND - patient profile Abb. 27: TRANSCEND - study design Abb. 28: TRANSCEND - study design Abb. 29: TRANSCEND - primary end point Zum letzten Bild
Abbildung 26: TRANSCEND - patient profile
Patients in TRANSCEND will be 55 years of age or more. As in ONTARGET, they will be at high risk of cardiovascular disease due to a history of coronary artery disease, stroke, peripheral vascular disease or diabetes mellitus type 1 or 2 with end-organ damage (microalbuminuria, abnormal ankle/brachial index [<0.8] or left ventricular hypertrophy). Patients with congestive heart failure will not be included. Patients will also be intolerant to treatment with ACE inhibitors. TRANSCEND will aim to recruit a total of 5000 patients.
 
TRANSCEND - patient profile
Vorheriges Bild Nächstes Bild   


Abbildung 26: TRANSCEND - patient profile
Patients in TRANSCEND will be 55 years of age or more. As in ONTARGET, they will be at high risk of cardiovascular disease due to a history of coronary artery disease, stroke, peripheral vascular disease or diabetes mellitus type 1 or 2 with end-organ damage (microalbuminuria, abnormal ankle/brachial index [<0.8] or left ventricular hypertrophy). Patients with congestive heart failure will not be included. Patients will also be intolerant to treatment with ACE inhibitors. TRANSCEND will aim to recruit a total of 5000 patients.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung